je.st
news
Tag: cancer
Actress Bellamy Young, Merck, and Leading Lung Cancer Advocates Urge Those Impacted by Lung Cancer to Test. Talk. Take Action.
2016-11-29 13:00:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. Young to Help Educate on the Importance of Biomarker Testing in Non-Small Cell Lung Cancer KENILWORTH, N.J.--(BUSINESS WIRE)--Acclaimed actress and singer Bellamy Young lost her father to lung cancer, and she is now sharing her personal experience as part of Test. Talk. Take Action., a new awareness campaign focused on increasing peoples understanding of biomarkers and the role they play in the treatment of non-small cell lung cancer (NSCLC). Language: English Contact: MediaMerckCourtney Ronaldo, 908-236-1108orChristiana Pascale, 212-257-6722 Media Capsule: iframes are not supported by your browser. Ticker Slug: Ticker: MRK Exchange: NYSE read more
FDA Grants Priority Review to Mercks Supplemental Biologics License Application (sBLA) Seeking Approval for KEYTRUDA (pembrolizumab) for New Indication in Microsatellite Instability-High Cancer
2016-11-28 13:00:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) accepted for review the supplemental Biologics License Application (sBLA) for KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, for the treatment of previously treated patients with advanced microsatellite instability-high (MSI-H) cancer. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orKim Hamilton, 908-740-1863orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: review
application
license
approval
Mercks KEYTRUDA (pembrolizumab) Significantly Improves Overall Survival Compared to Chemotherapy in Previously Treated Patients with Advanced Bladder (Urothelial) Cancer
2016-11-12 17:45:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. First Presentation of Data from Phase 3 KEYNOTE-045 Study Presented at the Society for Immunotherapy of Cancers (SITC) 31 st Annual Meeting KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from the pivotal KEYNOTE-045 study investigating the use of KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, in patients with advanced bladder (urothelial) cancer previously treated with platinum-containing chemotherapy. As previously announced, KEYTRUDA was superior to investigator-choice chemotherapy for the primary endpoint of overall survival (OS) in this phase 3 study, and was stopped early. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orCourtney Ronaldo, 908-236-1108orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: advanced
compared
previously
significantly
22/11/2016 - BIFM Scotland: Tour and Presentation at the Aberdeen Maggie’s Cancer Centre
2016-11-09 09:29:31| BIFM Events
Tags: centre
tour
presentation
cancer
Cancer survivor: 'I was sacked for having lymphoma'
2016-11-07 01:08:32| BBC News | Business | UK Edition
Cancer survivor Terry Foster, 58, says he was sacked after being diagnosed with lymphoma, as his company felt he wouldn't be able to handle the stress of the job.
Tags: cancer
survivor
lymphoma
sacked
Sites : [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] next »